Updated:
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center was established in 1884. Selwyn M. Vickers serves as President and CEO. The endowment supports the center's core...
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center was established in 1884. Selwyn M. Vickers serves as President and CEO. The endowment supports the center's core activities in oncology treatment and research rather than originating from a single family fortune. The endowment deploys capital across private equity, public equities, and real estate. Private equity represents 22.25% of assets. Confirmed holdings include Paige.AI, Flare Therapeutics, and Blue Note Therapeutics through MSK Ventures. Geographic exposure centers on the United States with additional activity in biotechnology spinouts. Direct secondaries and co-investments supplement fund commitments. The investment office oversees $8.2 billion with 19,518 total staff across the institution. Additional facilities operate in Uniondale, NY and Montvale, NJ. MSK Ventures functions as the dedicated vehicle for early-stage biotechnology investments. In May 2025 the center sponsored the ASCO Annual Meeting with speakers addressing CAR T cell trials. Board governance separates investment decisions from clinical operations through an Investment Committee that includes Jason Klein. Scott M. Stuart chairs the Board of Trustees while external trustees such as Stanley Druckenmiller provide oversight on capital allocation.
General information
Firm type
Endowment / Foundation
Year founded
1884
Location
Region
North America
Country
United States
City
New York
Corporate office
1275 York Avenue, New York, NY 10065, United States
Principals
Jason Klein
Senior Vice President and Chief Investment Officer
Selwyn M. Vickers
President and CEO
Scott M. Stuart
Chairman of the Board of Trustees
Marie-Josée Kravis
Vice Chair of the Board of Trustees
Sector focus
Frequently asked questions
Who runs investment decisions at Memorial Sloan Kettering Cancer Center?
Jason Klein serves as Senior Vice President and Chief Investment Officer. The Investment Committee reports to the Board of Trustees chaired by Scott M. Stuart.
Does Memorial Sloan Kettering Cancer Center participate in fund commitments or only direct deals?
The endowment uses both fund commitments and direct investments. MSK Ventures executes direct and co-investment activity in biotechnology companies.
What investment stages does Memorial Sloan Kettering Cancer Center typically target?
Activity spans early-stage seed through expansion and late-stage rounds. Holdings include seed and startup biotechnology companies alongside public equity positions.
Which sectors does Memorial Sloan Kettering Cancer Center explicitly prioritize?
The endowment focuses on healthcare, biotechnology, and venture capital. Public positions include healthcare companies such as Y-mAbs Therapeutics and ORIC Pharmaceuticals.
How is Memorial Sloan Kettering Cancer Center related to MSK Ventures?
MSK Ventures operates as the institution's venture capital arm. It holds limited partner positions in companies including Flare Therapeutics and Blue Note Therapeutics.
Where does the underlying capital supporting the endowment come from?
Capital derives from institutional operations, philanthropy, and investment returns. No single family wealth source is disclosed.
Does Memorial Sloan Kettering Cancer Center maintain philanthropic structures?
Cycle for Survival and The Society of Memorial Sloan Kettering operate as affiliated fundraising vehicles. Both direct proceeds to research and patient programs at the center.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: